EUnetHTA Response to COVID-19
We all are faced with an unprecedented situation, a reminder of how fragile we as individuals are, how fragile our societies remain. EUnetHTA is a network of specialists, dedicated in their own jurisdictions to excellence and the support of their individual health care systems. EUnetHTA derives its strength from its diversity, from the ability to […]
PTJA09 – Brolucizumab for the treatment of adults with neovascular (wet) age-related macular degeneration (AMD)
This is the pharmaceutical Joint Assessment PTJA09 on brolucizumab. In February 2020, the European Commission granted marketing authorisation for Beovu® (brolucizumab) for the treatment of adults with neovascular (wet) AMD. This Joint Assessment aims to compare the clinical effectiveness and safety of brolucizumab in the target patient population with relevant comparators according to the national […]
Statement from the EUnetHTA Secretariat on COVID-19
Due to the developing COVID-19 scenario affecting Europe and with regard to the policy responses emerging on a per national basis from certain areas, the EUnetHTA Secretariat is implementing precautionary changes to its planned 2020 events schedule. This is following instructions from the Executive Board of the Dutch National Healthcare Institute (ZIN) to revise plans […]
PTJA08 – Siponimod for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity
This is the pharmaceutical Joint Assessment PTJA08 – on siponimod for the treatment of active SPMS. In January 2020, the European Commission granted marketing authorisation for Mayzent® (siponimod) for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity. This Joint Assessment […]
PTJA06 – Polatuzumab vedotin in combination with bendamustine and rituximab for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for haematopoietic stem cell transplant
This is the pharmaceutical Joint Assessment PTJA06 – on polatuzumab vedotin for the treatment of relapsed/refractory DLBCL. In January 2020, The European Commission granted conditional marketing authorisation for Polivy® (polatuzumab vedotin), in combination with bendamustine plus MabThera® (rituximab) (BR), for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) […]
EUnetHTA Magazine – Winter 2020 – Now Available
We are pleased to publish the Winter 2020 issue of EUnetHTA Magazine, our quarterly update on HTA with input from network stakeholders. As always, we welcome your feedback so we can continue to improve how we can focus on developments in HTA. Happy reading! Click here for more.
PTJA05 – enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukaemia (AML) with an isocitrate dehydrogenase 2 (IDH2) mutation
On 6 Dec 2019, Celgene officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for enasidenib. Since no CHMP opinion will be granted at this stage, EUnetHTA closed this Joint Assessment on 12 Dec 2019. The final Project Plan for the applied […]
Patient group input requested for a new Joint Assessment on a medicinal product for tuberculosis.
EUnetHTA deems patient involvement very important in the production of Joint Assessment reports. We recognise that patients and those who support them have unique knowledge about what it is like to live with a specific disease or medical condition. We believe patient groups can help us understand patients’ unique perspectives by collecting and presenting patients’ […]
Open Call for Patient Group Input – Collaborative Assessment of (bariatric) surgical methods for treatment of morbid obesity
EUnetHTA recently started a new Collaborative Assessment of different surgical methods to treat morbid obesity To find out about participation, please read more here. Input submissions will be received through EOB, 20th March, 2020 EUnetHTA deems patient input very important in the production of Collaborative Assessment reports. We recognise that patients and those who support them […]
EUnetHTA 2020 Forum
The EUnetHTA 2020 Forum was originally planned to be held on 2nd April at Zorginstituut Nederland (ZIN), the Dutch Health Care Institute, in Diemen near Amsterdam. However, due to the ongoing Covid-19 pandemic, the Forum had to be postponed. in light of this, we are, however, pleased to offer the accompanying Welcome Guide that was […]
